Your browser doesn't support javascript.
loading
Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors.
Zhai, Yinghong; Hu, Fangyuan; Shi, Wentao; Ye, Xiaofei; Xu, Jingfang; Guo, Xiaojing; Cao, Yang; He, Jia; Xu, Feng.
  • Zhai Y; Clinical Research Center, School of Medicine, Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University, Shanghai, China.
  • Hu F; Department of Medical Service, Naval Hospital of Eastern theater, Zhejiang, Zhoushan, China.
  • Shi W; Department of Health Statistics, Second Military Medical University, Shanghai, China.
  • Ye X; Clinical Research Center, School of Medicine, Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University, Shanghai, China.
  • Xu J; Department of Health Statistics, Second Military Medical University, Shanghai, China.
  • Guo X; Department of Health Statistics, Second Military Medical University, Shanghai, China.
  • Cao Y; Department of Health Statistics, Second Military Medical University, Shanghai, China.
  • He J; Department of Health Statistics, Second Military Medical University, Shanghai, China.
  • Xu F; Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden.
Expert Opin Drug Saf ; 22(9): 857-869, 2023.
Article en En | MEDLINE | ID: mdl-37070462
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibrilación Atrial / Cardiopatías Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibrilación Atrial / Cardiopatías Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article